Lipoprotein deficiency is a group of conditions in which the body produces too few lipoproteins, the particles that ferry fats and cholesterol through the bloodstream. Because these particles carry fat-soluble vitamins and supply cells with essential lipids, having too few of them leads to problems that extend far beyond a low cholesterol reading on a lab report. The causes range from rare inherited gene mutations that shut down lipoprotein assembly to acquired conditions like severe illness or thyroid dysfunction that temporarily suppress lipoprotein levels. What makes these disorders tricky is that low cholesterol is usually considered good news, so lipoprotein deficiency often flies under the radar until fat-soluble vitamin shortfalls start damaging the eyes, nerves, or blood.
What Lipoproteins Actually Do
Lipoproteins are tiny spherical packages built from fat on the inside and protein on the outside. Their job is to move triglycerides, cholesterol, and fat-soluble vitamins (A, D, E, and K) from the gut and liver to the rest of the body. The major classes you see on a standard lipid panel, LDL and HDL, are just two members of a larger family that includes chylomicrons (which carry dietary fat from the intestine) and VLDL (which exports fat made by the liver). A protein called microsomal triglyceride transfer protein, or MTP, is essential for assembling the biggest of these particles; it loads lipids onto a scaffold protein called apolipoprotein B (apoB) so the finished lipoprotein can be released into the bloodstream.1PubMed Central. The crystal structure of human microsomal triglyceride transfer protein When any link in this assembly chain breaks, whether MTP itself, apoB, or the enzymes that process lipoproteins after they enter the blood, lipoprotein levels drop and fat-soluble nutrients cannot reach the tissues that need them.
Abetalipoproteinemia
Abetalipoproteinemia is the most severe inherited form of lipoprotein deficiency. It is caused by mutations in the MTTP gene, which encodes MTP. Without functional MTP, the intestine cannot package dietary fat into chylomicrons and the liver cannot assemble VLDL. The result is a near-total absence of apoB-containing lipoproteins in the blood.2PubMed. Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein Cholesterol and triglyceride levels are extremely low, and fat-soluble vitamins are poorly absorbed from the gut.
Symptoms typically show up in infancy. Babies with abetalipoproteinemia develop fatty diarrhea (steatorrhea), poor weight gain, and growth retardation because dietary fat simply passes through unabsorbed.3PubMed. A tale of 2 cousins: An atypical and a typical case of abetalipoproteinemia One case report described a 12-month-old boy from consanguineous parents who presented with diarrhea, growth retardation, hypothyroidism, and kidney stones before being diagnosed.4PubMed Central. A Male Infant with Abetalipoproteinemia: A Case Report from Iran If the condition is not caught early, the chronic shortage of vitamins A, E, and K causes progressive damage to the retina, peripheral nerves, and muscles throughout childhood and adolescence.
The inheritance pattern is autosomal recessive, meaning a child must receive a defective copy of MTTP from each parent to develop the disease. Carriers, people with just one defective copy, are clinically normal. Abetalipoproteinemia is rare enough that no firm prevalence figure exists for the general population, but consanguinity (parents who are related) increases the odds substantially because it raises the chance both carry the same mutation.
Familial Hypobetalipoproteinemia
Familial hypobetalipoproteinemia, often shortened to FHBL, is a related but genetically distinct condition. Instead of a problem with MTP, FHBL is caused by mutations in the APOB gene itself, the gene encoding apolipoprotein B. These mutations produce a truncated, shortened version of the apoB protein that cannot carry its normal load of lipids.5Journal of Lipid Research. Familial hypobetalipoproteinemia and abetalipoproteinemia: a review Some of these truncated forms are so small they are undetectable on standard blood tests, which can delay diagnosis.6PubMed. Novel mutations of APOB cause ApoB truncations undetectable in plasma and familial hypobetalipoproteinemia
What sets FHBL apart from abetalipoproteinemia is the inheritance pattern and severity. A single defective copy of APOB (heterozygous FHBL) is enough to lower LDL cholesterol to roughly half the normal level. Two defective copies (homozygous FHBL) produce a picture that looks very similar to abetalipoproteinemia, with extremely low apoB-containing lipoproteins and all the associated vitamin-deficiency complications. The heterozygous form is far more common, possibly affecting as many as 1 in 1,000 to 1 in 3,000 people, though many go undiagnosed because their only obvious finding is unusually low LDL cholesterol on routine bloodwork.
The Cardiovascular Paradox and Liver Risk
You might assume that near-zero LDL cholesterol would be nothing but good news for the heart. For heterozygous FHBL, that assumption is partly correct. A study comparing FHBL individuals with matched controls found that arterial stiffness was significantly lower in FHBL and that the usual vascular damage caused by traditional risk factors like high blood pressure and smoking appeared to be blunted by very low apoB-containing lipoprotein levels.7PubMed. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia Loss-of-function mutations in a related gene, PCSK9, that also lower LDL cholesterol appear to protect against coronary heart disease and seem largely benign.8PubMed Central. Common and rare gene variants affecting plasma LDL cholesterol
But the cardiovascular benefit has a flip side. When the liver cannot export fat via VLDL, that fat accumulates inside liver cells. The same study found that fatty liver (hepatic steatosis) was present in about 54% of FHBL individuals compared with 29% of controls, and the severity was also greater.7PubMed. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia Over decades, this trapped fat can progress to inflammation and liver damage. It is one of the clearest examples in medicine of a tradeoff: lower cardiovascular risk purchased at the cost of higher hepatic risk. That tradeoff is why even “mild” heterozygous FHBL needs monitoring.
Tangier Disease and Other HDL Deficiencies
Not all lipoprotein deficiencies involve the apoB side of the ledger. Tangier disease is a rare autosomal recessive condition caused by mutations in the ABCA1 gene, which encodes a transporter protein responsible for moving cholesterol out of cells and onto nascent HDL particles.9PubMed Central. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population Without functioning ABCA1, HDL cholesterol is nearly absent from the blood and cholesterol piles up inside tissues instead, particularly in the tonsils, liver, spleen, and nerves. People with Tangier disease often develop enlarged, orange-tinged tonsils (a classic exam finding), peripheral neuropathy, and accelerated atherosclerosis despite having very low total cholesterol.10PubMed Central. Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease
Another HDL-related deficiency involves the enzyme LCAT (lecithin cholesterol acyltransferase), which converts free cholesterol on HDL particles into a storage-ready form. Without LCAT, HDL remains immature and is rapidly cleared from the blood, leading to very low HDL levels. LCAT deficiency can cause corneal opacification, mild anemia, and progressive kidney disease. Whether it increases heart disease risk has been surprisingly hard to pin down; imaging studies of LCAT-deficient patients have not yielded a clear answer, and researchers remain divided on whether the enzyme is protective or neutral with respect to atherosclerosis.11PubMed Central. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor?
Familial Chylomicronemia Syndrome
Familial chylomicronemia syndrome (FCS) sits at the opposite end of the lipid spectrum from the conditions above. Rather than a shortage of lipoprotein assembly, the problem in FCS is an inability to break lipoproteins down after they enter the bloodstream. The most common cause is biallelic (two-copy) mutations in the LPL gene, which encodes lipoprotein lipase, the enzyme that strips triglycerides from chylomicrons and VLDL so tissues can use them for energy. Less often, mutations in genes encoding LPL’s cofactors or docking proteins, including APOC2, APOA5, LMF1, and GPIHBP1, produce the same result.12PubMed. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia
The hallmark of FCS is extreme hypertriglyceridemia: blood triglyceride levels can soar above 1,000 mg/dL and sometimes well beyond 2,000 mg/dL. A blood sample drawn from someone with FCS may look milky because of the massive number of uncleared chylomicrons floating in it. The most dangerous acute complication is pancreatitis, which can be life-threatening. Recurrent abdominal pain, eruptive xanthomas (small yellow bumps on the skin), and an enlarged liver and spleen are other common features.
Interestingly, even people carrying just one defective LPL copy (heterozygotes) can sometimes develop severe hypertriglyceridemia with triglycerides above 2,000 mg/dL and complications like pancreatitis, particularly when additional metabolic stressors are present.13Termedia / Archives of Medical Science. Lipoprotein lipase deficiency: heterozygotes match homozygotes in severity That finding challenges the traditional view that only people with two defective copies are at serious risk and underscores why genetic testing can be informative even for patients who do not fit the classic two-copy picture.
Secondary and Acquired Causes
Not every case of unusually low lipoprotein levels traces to an inherited gene defect. Several acquired conditions can push lipoprotein levels down, sometimes dramatically.
Critical illness is one of the most striking triggers. Patients with sepsis, major trauma, extensive surgery, or severe burns show an immediate and sustained drop in LDL, HDL, and total cholesterol. The causes are multifactorial: reduced nutritional intake, increased scavenging of lipoproteins by immune and endothelial cells, and diversion of cholesterol toward cortisol and other stress-related metabolites all play a role.14PubMed Central. Impact of critical illness on cholesterol and fatty acids: insights into pathophysiology and therapeutic targets In an ICU setting, severely low cholesterol has even been explored as a marker of disease severity and prognosis, though it is not yet used routinely for that purpose.
Thyroid status is another important variable. Hyperthyroidism (an overactive thyroid) speeds up LDL receptor activity and cholesterol clearance, which can mask an underlying tendency toward high cholesterol. When the thyroid is treated and hormone levels normalize, cholesterol can jump up sharply. One documented case involved a woman treated for Graves’ disease whose total cholesterol rose from normal to 257 mg/dL and LDL to 174 mg/dL once she reached a euthyroid state.15PubMed Central. Dyslipidemia Unmasked by the Treatment of Graves’ Disease: The Link Between Cholesterol Metabolism and Thyroid Hormones The reverse scenario, hypothyroidism raising cholesterol, is more widely known, but the hyperthyroid side matters for lipoprotein deficiency because it can temporarily create misleadingly low readings that disappear once the thyroid is controlled.
Severe malnutrition, chronic liver disease, and certain cancers (especially hematologic malignancies) can also depress lipoprotein production. In these situations, the low lipoprotein level is a downstream effect of the primary illness, not a standalone genetic disorder, and treating the underlying condition typically restores normal levels.
How Fat-Soluble Vitamin Deficiency Drives Symptoms
For the genetic lipoprotein deficiencies, the day-to-day damage is not caused by low cholesterol per se. It is caused by the chronic shortage of vitamins A, E, K, and sometimes D that results from fat malabsorption. Understanding which vitamin drives which symptom explains the otherwise puzzling variety of problems these patients face.
- Vitamin E: The earliest and most disabling neurological features, including sensory ataxia (difficulty coordinating movement), peripheral neuropathy, and progressive muscle weakness, stem from vitamin E deficiency. Vitamin E is a fat-soluble antioxidant that protects nerve cell membranes, and without it, nerves in the spinal cord and periphery degenerate over years.16PubMed Central. Abetalipoproteinemia: two case reports and literature review
- Vitamin A: Retinitis pigmentosa, a form of progressive vision loss caused by retinal degeneration, is a well-recognized complication. In abetalipoproteinemia, it tends to be “atypical” in its appearance on eye exams but produces similar functional loss.17PubMed Central. Clinical, hematological, and imaging observations in a 25-year-old woman with abetalipoproteinemia
- Vitamin K: Without adequate vitamin K, the liver cannot produce several clotting factors, leading to a tendency to bleed or bruise easily (coagulopathy).
- Vitamin D: Poor absorption of vitamin D can contribute to weakened bones over time, though this is often less clinically prominent than the vitamin E and A deficiencies.
Deafness has been reported in some cases of abetalipoproteinemia, though it is rare and its exact mechanism is not fully understood.17PubMed Central. Clinical, hematological, and imaging observations in a 25-year-old woman with abetalipoproteinemia Another distinctive finding on blood work is acanthocytosis, the appearance of spiky, misshapen red blood cells. The abnormal lipid composition of the red cell membrane, with increased sphingomyelin and decreased lecithin, changes the cell’s shape and flexibility.18PubMed. Alterations in erythrocyte membrane lipids in abetalipoproteinemia: phospholipid and fatty acyl composition Acanthocytes are not just a curiosity; their presence on a blood smear is sometimes the first clue that prompts further workup for lipoprotein deficiency.
Treatment and Long-Term Outlook
There is no way to fix the underlying genetic defect in abetalipoproteinemia or homozygous FHBL with current standard therapies. Management focuses on limiting fat malabsorption and aggressively replacing the vitamins that cannot be absorbed normally. High-dose oral supplementation with vitamins A, E, K, and sometimes D is the mainstay of treatment for both abetalipoproteinemia and the severe forms of FHBL.19PubMed Central. Current Diagnosis and Management of Abetalipoproteinemia 20PubMed Central. Current Diagnosis and Management of Familial Hypobetalipoproteinemia 1 The doses needed are far beyond what a healthy person would take, because so little is absorbed through the gut.
Dietary modification is the other pillar. Patients are typically placed on a low-long-chain-fat diet, with much of their fat intake coming from medium-chain triglycerides (MCT oil). Medium-chain fats are absorbed directly into the portal vein without needing to be packaged into chylomicrons, bypassing the broken assembly pathway. A long-term follow-up of a Greek family with abetalipoproteinemia found that after 33 years of strict dietary modification with MCT oil and close surveillance, all patients were alive without any sign of liver dysfunction.21PubMed Central. Thirty-Three Years Follow-Up of a Greek Family with Abetalipoproteinemia: Absence of Liver Damage on Long-Term Medium Chain Triglycerides Supplementation That kind of outcome was not always expected for a disease once considered uniformly devastating, and it speaks to what consistent management can achieve.
When vitamin supplementation is started early and maintained, some patients with abetalipoproteinemia live into their seventies or eighties.19PubMed Central. Current Diagnosis and Management of Abetalipoproteinemia The neurological and retinal damage, however, tends to be irreversible once it occurs, which is why early diagnosis matters so much. In infants presenting with unexplained steatorrhea and growth failure, checking a lipid panel and looking for acanthocytes on a blood smear can point toward the diagnosis well before permanent harm is done.22Discover Medicine. Abetalipoproteinemia a rare case of malabsorption disorder with diagnostic insights: a case report
For FCS, treatment centers on an extremely low-fat diet (often less than 20 grams per day) to keep chylomicrons from flooding the bloodstream. Standard triglyceride-lowering drugs like fibrates and omega-3 fatty acids have limited efficacy in FCS because they work partly through lipoprotein lipase, which is the very enzyme that is defective. Management remains challenging, and acute pancreatitis can be a recurring threat.
Gene-Based Therapies on the Horizon
The rarity and genetic clarity of lipoprotein deficiency disorders make them appealing targets for gene therapy. The most notable attempt to date was Glybera, an AAV1-based gene therapy designed to deliver a functional copy of the LPL gene to muscle cells in patients with lipoprotein lipase deficiency. Glybera was conditionally approved in Europe, making it one of the first gene therapies ever authorized in the Western world.23PubMed. Gene-based therapies in lipidology: current status and future challenges It was eventually withdrawn from the market, not because of safety problems, but because demand was too low and the price too high to be commercially viable for such a tiny patient population. Still, it provided proof of concept that replacing a defective lipid-metabolism gene in humans is technically feasible.
On the HDL side, recombinant LCAT is being developed as an enzyme-replacement therapy for patients with genetic LCAT deficiency, primarily to prevent the kidney damage that is the most serious long-term complication of that condition.11PubMed Central. Lecithin cholesterol acyltransferase: an anti- or pro-atherogenic factor? Researchers have also speculated about its potential use in acute coronary syndrome, though that application remains early-stage. For abetalipoproteinemia and homozygous FHBL, no gene therapy has reached clinical trials, but the knowledge that a single gene is responsible in each case makes them logical candidates as delivery platforms improve and costs come down.
When Low Cholesterol Deserves a Closer Look
Most people who see low LDL cholesterol on their lab results have nothing to worry about. But there is a threshold, generally an LDL below about 50 mg/dL without any cholesterol-lowering medication, where a physician may want to investigate further. Unexplained very low LDL in a child with digestive problems, or in an adult with fatty liver and no obvious dietary cause, can be the first sign of FHBL or another lipoprotein assembly defect. Similarly, an HDL below about 20 mg/dL in someone who does not have severe malnutrition or liver failure raises the possibility of Tangier disease or LCAT deficiency.
Genetic testing has become more accessible and can identify mutations in MTTP, APOB, ABCA1, LPL, and other relevant genes. A consensus statement from lipid specialists has recommended genetic testing for patients with unexplained severe dyslipidemias, including unusually low as well as unusually high lipid levels, to guide family screening and long-term monitoring.24Journal of Clinical Lipidology. Clinical genetic testing for familial hypercholesterolemia and other dyslipidemias: An Expert Clinical Consensus Statement of the National Lipid Association For family members of someone with a known mutation, testing can identify carriers and, in the case of autosomal dominant FHBL, individuals who may benefit from liver monitoring or vitamin supplementation even if they feel fine.